Meet Paulo A. Garcia, the CEO and co-founder of Kytopen Corporation, a company focused on the development and commercialization of Flowfect™ technology. This novel innovation is designed to enhance the delivery of molecules into immune cells, which can be challenging to transfect. Dr. Garcia's inventions merge engineering and biology, and his Ph.D. in Bioengineering and Biomedical Engineering from Virginia Tech equipped him with the knowledge required for the job. Additionally, his B.S. in Physics from Randolph-Macon College provides him with a comprehensive understanding of the fundamental principles governing the universe.

Before joining Kytopen, Dr. Garcia worked at the Massachusetts Institute of Technology as a research scientist and postdoctoral researcher. At MIT, he co-invented the Flowfect™ technology, which combines microfluidics and automation to improve reliability, speed, and ease of use in cell engineering. Dr. Garcia has published numerous scientific articles and holds patents in the fields of biology and engineering.

Dr. Garcia's expertise in hard-to-transfect immune cells and bioengineering has made him a valuable asset to Kytopen Corporation. Through the Flowfect™ technology, Kytopen is destined to become a leader in the field of cell and gene therapies. Additionally, Dr. Garcia's experience as a high school mathematics teacher at Benedictine High School demonstrates his commitment to promoting science education among young people.